Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 3, 2010

Cambrex Buys 51% of Zenara for $20M as First Stage in Overall Buyout of Indian Firm

Cambrex Buys 51% of Zenara for $20M as First Stage in Overall Buyout of Indian Firm

Expertise of combined entity will span APIs, delivery, formulation, and final dosage forms. [JLV Image Works - Fotolia.com]

  • Cambrex has enacted the first half of a two-stage buyout of Zenara Pharma through the acquisition of a 51% stake in the Indian firm for $20 million. Cambrex will acquire the remaining 49% in Zenara during early 2016. The purchase price will depend on EBITDA figures during 2011-2015. The new firm will be called Cambrex Zenara.

    Zenara specializes in the formulation of final dosage form products. Cambrex says this expertise will complement its own API and drug-delivery capabilities. The acquisition will also provide a development and manufacturing platform for Cambrex within the Indian Pharmaceutical market. More specifically, Cambrex believes the acquisition will make it one of the leading suppliers globally to the nicotine replacement therapy market through the provision of both APIs and finish dosage form products.

    Cambrex offers services for the manufacture of APIs, advanced intermediates, and enhanced drug-delivery products for branded and generic pharmaceuticals.

     

     



Related content

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »